Anheuser-Busch InBev SA/NV

source: coverage-next-full ticker: BUD step: 01 title: Business Model & Overview generated: 2026-05-28

Step 01 — Business Model & Overview

Key Findings

• BUD is the world's largest brewer by volume (~25% global share) [S9] and by revenue ($59.3B FY25 [S2]), with ~500 brands across ~50 countries.
• Operates as a vertically-integrated, asset-heavy global brewer + distributor: owns barley supply (in part), maltings, breweries, packaging, logistics, and in many EMs the direct-to-retail B2B platform (BEES) [S7].
• Profit pool concentrated in just three economies — US, Brazil, Mexico — which together contribute >60% of EBITDA [S7]. This is the central geographic concentration risk and opportunity.
• Three global brands (Budweiser, Corona, Stella Artois) anchor the premium portfolio; megabrand set (~70% of revenue) extends to Michelob Ultra, Modelo Mexico, Brahma, Skol, Beck's, Hoegaarden, Leffe [S7].
• Net positive for the thesis — global scale + diversified profit pool + vertical control + premium-portfolio compounding all genuine moat sources.

Implications for Thesis and Valuation

The business model has three valuation-relevant features:

1. Operating leverage from premium mix-shift — premium portfolio +6.3% revenue growth vs flat total volumes [S7]; even modest mix shifts move EBITDA.
2. Cash generation is structural, not cyclical — vertically-integrated + countercyclical beer category + low capex requirement (3.5% of revenue) → FCF $11.2B reliable [S4].
3. BEES B2B platform ($50B+ GMV [S7]) is an embedded distribution moat that competitors cannot easily replicate; this is the under-modeled asset in most sell-side decks.

Objective

Map BUD's business model — what they make, how they make money, how they distribute, where the profit pool sits, and what the value-chain layers are.

Narrative Analysis

What BUD does. Brews, packages, distributes, and markets beer (and a growing adjacent portfolio of hard seltzer, RTD cocktails, alcohol-free beer, and ready-mixed drinks) across ~50 countries. Output: roughly 580M HL of beer annually [S9].

Revenue model — by structural layer:

1. Megabrand portfolio (~70% of revenue). The core profit engine: Budweiser, Corona, Stella, Michelob Ultra, Modelo (Mexico/global ex-US — STZ owns US), Brahma, Skol, Beck's, Hoegaarden, Leffe [S7]. Wholesale to distributors and retail; premium-positioned variants carry 2-3x the EBITDA per HL of standard brands.
2. Regional / local brands (~25% of revenue). ~500 SKUs covering value tier in specific geographies — Aguila (Colombia), Cass (Korea), Harbin (China), Quilmes (Argentina). Lower margin but volume defenders.
3. Beyond Beer (~5% of revenue, +23% growth) [S7]. Cutwater Spirits (US RTD cocktails — triple-digit growth), NUTRL hard seltzer, Mike's Hard Lemonade, Brutal Fruit (S Africa), Flying Fish, Babe Wine. Adjacency expansion; high-margin variable-cost adjacencies that share distribution.
4. Alcohol-free / no-low alc (~3% of revenue, +34% growth) [S7]. Corona Cero, Budweiser Zero, Stella Zero, Beck's Blue. Among fastest-growing sub-segments globally [S10]; ~20% better unit margin than alcoholic counterparts per AB InBev disclosure.
5. BEES B2B + DTC platform. Not a separate revenue line — a distribution enabler. ~$50B GMV across 31 markets [S7]; in places like Brazil and Mexico it directly serves >2M small retailers and bars, with last-mile delivery and credit. Direct economic benefit: better mix, less promo waste, real-time demand signal. Hard to value separately but real strategic moat.

How money is made — economics:

• Net revenue per HL: ~$102 globally (FY25 = $59.3B / 580M HL ≈ $102/HL)
• EBITDA per HL: ~$36 (= $21.06B / 580M HL ≈ $36/HL) — premium markets >$50/HL, EM value markets <$25/HL [S7]
• Premium HL carry +50-80% EBITDA per HL premium vs standard
• Capex: ~$3.7B annually = 6.2% of revenue (FY25), down from 10.4% in FY21 [S4]
• Working capital: structurally negative ($-9.7B WC FY25 [S3]) — suppliers and distributors finance the business; this is a meaningful float advantage

Value-chain layer map:

Evidence and Sources

• Revenue $59.32B FY25, EBITDA $21.06B [S2][S7]
• Volume base ~580M HL (industry estimates triangulated with IWSR + 20-F MD&A) [S9]
• Segment mix: Middle Americas 29%, NA 24%, SA 20%, EMEA 16%, APAC 10% [S7]
• Premium portfolio ~35% of revenue, +6.3% growth [S7]
• Beyond Beer +23%, alcohol-free +34% [S7]
• BEES GMV ~$50B [S7]
• ~144,000 employees [S7]

Assumption Register Updates

• A03 — Premium portfolio ~35% of revenue (Estimate, Med sensitivity) [S7]
• A04 — Volume base ~580M HL (Estimate, Low sensitivity) [S7][S9]
• A05 — Megabrand revenue concentration ~70% (Fact, Low sensitivity) [S7]

Tables and Calculations

Revenue mix by segment (FY25)

Revenue mix by brand-tier (FY25)

Per-unit economics (FY25 estimates)

Open Questions and Data Gaps

• BEES profit contribution not separately disclosed — treated as distribution enabler. Value-as-platform argument is qualitative.
• Volume HL estimates triangulated; precise volume is not in standardized IFRS statements.

Source Index

source: coverage-next-full ticker: BUD step: 12 title: Bull / Bear — Catalyst Debate generated: 2026-05-28

Step 12 — Bull / Bear — Catalyst Debate

Key Findings

• The debate over BUD is now structured as "recovery + capital return inflection" (bulls) vs "structural beer-volume decline + Bud Light brand impairment" (bears). The variance is meaningful but narrowing — Street is ~75% buy [S12].
• Recovery thesis dominates near-term Street narrative following Q1-26 +12% revenue print + the $6B buyback + ND/EBITDA <3x milestone.
• Bear case has not gone away — Bud Light volumes remain materially below pre-2023 levels (~30% down vs 2022 peak per industry sources [S8]); category volumes still falling.
• Catalysts to watch: (1) Q2-26 6-K (Jul/Aug) — confirms US Michelob Ultra share, (2) $6B buyback progress, (3) any segment-level US recovery data.

Implications for Thesis and Valuation

This step is critical input to /complete-coverage Step_15 (scenarios) and the public /stocks page Bull/Bear panels. The decision on this debate determines the entire valuation framing.

Objective

Steelman both the bull and bear cases using the analyst-debate framework adapted for the no-transcripts path. Methodology note: since earnings call transcripts are not loaded in /coverage-next-full, this step uses (a) 20-F MD&A, (b) FY25 6-K press release [S7], (c) trade-press synthesis [S8][S13], (d) sell-side consensus reports [S12], and (e) news flow [S10].

Narrative Analysis

THE BULL CASE — Recovery + Capital Return Inflection

Core argument: BUD has crossed the ND/EBITDA 3.0x threshold, the worst of the Bud Light disruption is behind, premium portfolio compounds at +6%, and the $6B buyback authorization signals management's conviction in cash-flow runway. The stock should re-rate toward a "post-deleveraging high-FCF compounder" multiple, similar to Coca-Cola / Diageo (15-16x EV/EBITDA vs BUD at 12x).

Key supports:

1. Capital return inflection is real and observable. Buyback FY23 $362M → FY25 $2,301M → $6B new authorization [S14]. Dividend +22% FY24 + 15% FY25. Total shareholder yield approaching 5% at current price.

2. Underlying business is healthier than the headline. Organic revenue +3.1% / organic EBITDA +4.5% in FY25 [S7]. 65% of markets growing revenue; 75% growing EBITDA. The "premium portfolio +6.3%" growth is the real compounding engine, not aggregate volume.

3. US recovery underway. Michelob Ultra is now the #1 US beer by dollar share in selected weeks [S7]. The Bud Light decline rate is decelerating; the brand is no longer in free-fall. Net US revenue is recovering even as Bud Light specifically remains weak. BUD has demonstrated that its portfolio moat (multiple brands) can withstand single-brand impairment.

4. Beyond Beer + alcohol-free are real growth engines. Cutwater triple- digit growth; Corona Cero +34%; alcohol-free category +8% globally; BUD gaining ground vs Heineken's first-mover lead [S7][S10]. These adjacencies are high-margin and increase BUD's category share-of-throat.

5. BEES B2B platform is structurally undervalued. ~$50B GMV [S7] running through 31 markets; this is a logistics/data moat that would be worth ~$5-10B as a standalone tech asset. Today it's bundled into "AB InBev distribution" and gets no separate credit.

6. Multiple expansion case. BUD at 12x EV/EBITDA vs Heineken 11.5x, KO ~22x, Diageo ~16x. As deleveraging finishes (~FY28), BUD should converge toward the Diageo/KO range, implying ~15x = +25% upside on multiple alone.

THE BEAR CASE — Structural Volume Decline + Brand Impairment

Core argument: Beer is a structurally declining category in mature markets; BUD's Bud Light brand is permanently impaired and may never reach pre-2023 share; premium mix-shift will eventually cap; debt remains massive ($73B gross); the founder block forecloses LBO/breakup optionality.

Key supports:

1. Industry volume decline is structural, not cyclical. Global beer -1% volume in 2025 per IWSR [S9]; mature markets flat-to-declining. Gen Z drinks less; GLP-1s reduce alcohol consumption; cannabis displaces beer in US states. Premium mix-shift can offset for a while but math eventually constrains it: premium share already at 35%, ceiling is probably 45-50%.

2. Bud Light brand impairment may be permanent. Some ex-AB Inbev execs have publicly stated Bud Light hasn't recovered [S8]. Bud Light volumes remain ~30% below 2022 peak per industry sources [S8]. The Modelo Especial (now Mich Ultra) US #1 position represents a permanent rebalancing in the brand portfolio, with associated marketing-cost inefficiency.

3. $61B net debt is still huge. ND/EBITDA 2.87x is "below 3x" but is still high in absolute terms; interest cost ~$4.5B/yr; sensitivity to rate moves real. The "deleveraging completed" celebration assumes target ~2.0x, but mgmt has explicitly said this is "optimal", not "required" — capital return acceleration could pause if EBITDA growth disappoints.

4. Founder block forecloses optionality. Stichting AK extension to 2034 [S11] eliminates the activist + LBO premium that otherwise might be embedded in valuation. The maximum-extraction breakup case (e.g., selling US operations to Constellation; selling Ambev minority to local Brazilian buyers) is structurally impossible.

5. APAC weakness is uncertain. China consumer slowdown is real; government stimulus has been incremental; mgmt has not put a recovery timeline on the table. APAC ~10% of revenue but disproportionately profitable in premium positions.

6. Multiple compression risk. If volume decline accelerates (especially if Bud Light deteriorates further), BUD could compress toward Molson Coors multiples (7-8x EV/EBITDA), representing ~35-40% downside.

Synthesizing the debate

The bull case is more correlated to observable data (deleveraging milestone, $6B buyback, Q1-26 +12% revenue) and less reliant on assumptions about category structure.

The bear case is more reliant on long-tail structural arguments that may or may not materialize over the forecast horizon. Bud Light brand-recovery is a real uncertainty but is largely priced — BUD trades at a discount to KO/ Diageo despite better deleveraging profile.

Consensus: 75% buy / 17% hold / 0% sell [S12]. Average PT $89.90 vs $82.69 spot = ~9% upside [S12]. The Street is structurally bullish but the debate is alive.

The /complete-coverage Step_15 scenarios should weight Bull / Base / Bear roughly 40% / 40% / 20% to reflect this debate.

Evidence and Sources

• ND/EBITDA 2.87x [S14]
• $6B buyback [S14]
• Organic revenue +3.1% FY25 / +12% Q1-26 [S7][S2]
• Premium +6.3% [S7]; Beyond Beer +23%; alcohol-free +34% [S7]
• Bud Light volumes still ~30% down vs 2022 [S8]
• Founder block extended to 2034 [S11]
• Street ratings 10 buy / 2 hold / 0 sell [S12]
• Industry volumes -1% [S9]

Assumption Register Updates

• A32 — Bull case organic rev growth FY26-28 = +3.5 to +4.5% (Estimate, High sens) [S7][S12]
• A33 — Bear case organic rev growth FY26-28 = +1.0 to +2.0% (Estimate, High sens) [S9]
• A34 — Bull/Base/Bear weighting for Step 15 = 40/40/20 (Judgment, Med sens) [S12]

Tables and Calculations

Bull/Bear scoreboard

Catalyst calendar (next 12 months)

Open Questions and Data Gaps

• Without transcripts, can't gauge mgmt tone on FY26 organic growth guidance ranges.
• Bud Light SKU-level Circana data not directly accessible to this research.

Next-Step Dependencies

• /complete-coverage Step_13 will use the Bull/Base/Bear inputs for forecast
• Step_14 will value the scenarios
• Step_15 will produce probability-weighted target with the 40/40/20 weighting
• Public /stocks page will surface the 3-bullet Bull and Bear cases below

Source Index

Bull Case — 3 bullets

• Capital return inflection unlocked. ND/EBITDA crossed below 3.0x for the first time since the 2016 SABMiller deal (now 2.87x); $6B new buyback program underway + progressive +15% dividend; total shareholder yield ~5% with ~$15B further deleveraging headroom before mgmt's ~2.0x target.
• Premium portfolio compounds while volume is flat. Premium + super-premium +6.3% revenue growth, Beyond Beer +23%, alcohol-free +34% — mix-shift drives organic EBITDA +4.5% even with global beer volumes -1%; Q1-26 reported revenue inflected to +12.0% confirming the recovery is real.
• US "worst is past" + BEES optionality. Michelob Ultra captured #1 US beer dollar-share in selected 2025 weeks, demonstrating portfolio moat intact; BEES B2B platform at $50B GMV across 31 markets is a structurally undervalued distribution moat the Street largely ignores.

Bear Case — 3 bullets

• Bud Light brand may be permanently impaired. Volumes still ~30% below 2022 peak nearly 3 years post-controversy; Modelo Especial took #1 US beer status in 2023 and never gave it back; some ex-execs publicly state recovery has stalled; if Bud Light deteriorates further, US intangibles ($30-40B carrying value) face impairment risk.
• Structural category decline + GLP-1/wellness headwind. Global beer volumes -1%/yr structural; mature markets flat-to-declining; premium mix- shift has a ceiling (~45-50% of revenue) before it taps out; Gen Z drinks less, RTD cocktails and cannabis substitute, GLP-1s reduce alcohol consumption — these are durable headwinds the model cannot reverse.
• $73B debt + founder block cap optionality. Gross debt remains huge with $4.5B/yr interest expense; refinancing rates partially offset; meanwhile the Stichting AK founder voting block extension to 2034 eliminates activist/LBO/ breakup optionality that might otherwise support multiple expansion; the stock has to earn its return via execution alone.